Skip to main content
Premium Trial:

Request an Annual Quote

BioTrove, Gene Express to Co-Market Lung Cancer Risk Test

NEW YORK (GenomeWeb News) – BioTrove and Gene Express have struck an agreement to co-market a test for profiling certain indicators for the risk of lung cancer, BioTrove said today.
The test, called the Standardized NanoArray PCR, or SNAP, gene expression profiling system, uses BioTrove’s OpenArray nanofluidic PCR platform, Gene Express’ PCR measurement standards, and clinical knowledge from the University of Rochester School of Medicine and Dentistry.
The PCR analysis profiling system is a novel method for “consistent and accurate lung cancer risk analysis” that may be used in diagnostic laboratories or community hospitals, BioTrove said.
David Lester, Gene Express’ chief technology officer, said in a statement that the SNAP system “simplifies and standardizes” lab workflows and makes “genetic profiling viable and translatable” in diagnostic labs.
BioTrove’s OpenArray system allows scientists to conduct up to 3,072 independent PCR analyses simultaneously on up to 144 samples in a single plate, while Gene Express’ Standardized RT PCR, or StaRT-PCR, control for false negatives and false positives, BioTrove said.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.